123 related articles for article (PubMed ID: 28058864)
1. Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States.
Rubin JL; Thayer S; Watkins A; Wagener JS; Hodgkins PS; Schechter MS
Curr Med Res Opin; 2017 Apr; 33(4):667-674. PubMed ID: 28058864
[TBL] [Abstract][Full Text] [Related]
2. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Morris NJ; Konstan MW
J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
[TBL] [Abstract][Full Text] [Related]
3. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
4. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
[TBL] [Abstract][Full Text] [Related]
5. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
[TBL] [Abstract][Full Text] [Related]
7. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
Wagener JS; Rasouliyan L; VanDevanter DR; Pasta DJ; Regelmann WE; Morgan WJ; Konstan MW;
Pediatr Pulmonol; 2013 Jul; 48(7):666-73. PubMed ID: 22888106
[TBL] [Abstract][Full Text] [Related]
8. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Pasta DJ; Konstan MW
J Cyst Fibros; 2015 Nov; 14(6):763-9. PubMed ID: 25754096
[TBL] [Abstract][Full Text] [Related]
9. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.
Castner LM; Zimbric M; Cahalan S; Powell C; Caverly LJ
J Cyst Fibros; 2021 Nov; 20(6):926-931. PubMed ID: 33612403
[TBL] [Abstract][Full Text] [Related]
13. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
[TBL] [Abstract][Full Text] [Related]
14. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007.
Briesacher BA; Quittner AL; Fouayzi H; Zhang J; Swensen A
Pediatr Pulmonol; 2011 Aug; 46(8):770-6. PubMed ID: 21465674
[TBL] [Abstract][Full Text] [Related]
15. Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations.
Faino AV; Hoffman LR; Gibson RL; Kronman MP; Nichols DP; Rosenfeld M; Cogen JD
J Cyst Fibros; 2023 Jul; 22(4):630-635. PubMed ID: 36849332
[TBL] [Abstract][Full Text] [Related]
16. Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis.
Vanstone MB; Egan ME; Zhang JH; Carpenter TO
Pediatr Pulmonol; 2015 May; 50(5):441-6. PubMed ID: 25657016
[TBL] [Abstract][Full Text] [Related]
17. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
18. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Flume PA; Morris N; Konstan MW
J Cyst Fibros; 2016 Nov; 15(6):783-790. PubMed ID: 27139161
[TBL] [Abstract][Full Text] [Related]
19. The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.
Cogen JD; Whitlock KB; Gibson RL; Hoffman LR; VanDevanter DR
J Cyst Fibros; 2019 Nov; 18(6):851-856. PubMed ID: 31147301
[TBL] [Abstract][Full Text] [Related]
20. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
Sanders DB; Zhao Q; Li Z; Farrell PM
Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
